Ali M. Alghamdi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ali M. Alghamdi has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Abanoub Riad
Department of Public Health, Faculty of Medicine Masaryk University Brno Czech Republic
1 shared publication - Ali A. Almurikhi
Department of Family Medicine, King Fahad Specialist Hospital, Dammam 32253, Saudi Arabia
1 shared publication - Esra H. Alzaid
Department of Family Medicine, King Fahad Specialist Hospital, Dammam 32253, Saudi Arabia
1 shared publication - Fayez A. Alzahrani
Department of Family Medicine, King Fahad Specialist Hospital, Dammam 32253, Saudi Arabia
1 shared publication - Miloslav Klugar
JBI Center of Evidence-based Education and Arts Therapies, Faculty of Education, Palacky University, Olomouc, Czech Republic
1 shared publication - Safa S. Alsaad
Department of Family Medicine, King Fahad Specialist Hospital, Dammam 32253, Saudi Arabia
1 shared publication
Latest Publications
- Open Access
Side Effects of COVID-19 Vaccines Primer Doses: Experience of Saudi Healthcare Workers Participating in CoVaST-SA
Background: Side effects emerging after COVID-19 vaccines may adversely impact public confidence in vaccines. Therefore, this study was designed to explore the short-term side effects of COVID-19 vaccines as a part of the COVID-19 Vaccines Safety Tracking (CoVaST) study. Methods: A cross-sectional survey-based study was carried out to collect data from healthcare workers (HCWs) in Saudi Arabia. The study was initiated between June and December 2021. A validated questionnaire was used in this study consisting of four categories, including demographic characteristics and medical anamnesis of the participants, COVID-19-associated anamnesis, and side effects of vaccine uptake. Results: The study included 1039 participants, of which 70.2% were females, and their median age was 34. About 82.9% and 52.3% of the participants reported a minimum of both one local and systemic side effect, respectively. Females, young participants (≤34 years old), and non-obese participants had more potential to disclose post-vaccination side effects than their counterparts. Heterologous schedules and viral vector-based vaccines were linked with a greater rate of systemic side effects, whereas homologous vaccination schedules and mRNA-based vaccines were linked with a greater rate of local side effects. Conclusion: Future studies on COVID-19 vaccines should focus on the role of BMI, previous infection, and vaccination schedule in terms of vaccine safety and reactogenicity.
Open AccessSide Effects of COVID-19 Vaccines Primer Doses: Experience of Saudi Healthcare Workers Participating in CoVaST-SA
Background: Side effects emerging after COVID-19 vaccines may adversely impact public confidence in vaccines. Therefore, this study was designed to explore the short-term side effects of COVID-19 vaccines as a part of the COVID-19 Vaccines Safety Tracking (CoVaST) study. Methods: A cross-sectional survey-based study was carried out to collect data from healthcare workers (HCWs) in Saudi Arabia. The study was initiated between June and December 2021. A validated questionnaire was used in this study consisting of four categories, including demographic characteristics and medical anamnesis of the participants, COVID-19-associated anamnesis, and side effects of vaccine uptake. Results: The study included 1039 participants, of which 70.2% were females, and their median age was 34. About 82.9% and 52.3% of the participants reported a minimum of both one local and systemic side effect, respectively. Females, young participants (≤34 years old), and non-obese participants had more potential to disclose post-vaccination side effects than their counterparts. Heterologous schedules and viral vector-based vaccines were linked with a greater rate of systemic side effects, whereas homologous vaccination schedules and mRNA-based vaccines were linked with a greater rate of local side effects. Conclusion: Future studies on COVID-19 vaccines should focus on the role of BMI, previous infection, and vaccination schedule in terms of vaccine safety and reactogenicity.